HR 1843 · To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Referred to the House Committee on Energy and Commerce.
- Introduced
- Mar 5, 2025
- Latest action
- Mar 5, 2025
- Sponsor
- Rep. Neal P. Dunn [R-FL-2]
- Policy area
- Health
- Cosponsors
- 1
Summary
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
Recent actions
- Mar 5, 2025 Referred to the House Committee on Energy and Commerce.
- Mar 5, 2025 Introduced in House
- Mar 5, 2025 Introduced in House
Votes
No recorded votes are available for this bill.